Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfonylurea continuation, discontinuation, or replacement with linagliptin in type 2 diabetes on premixed insulin
ACTRN12615000732583Phase 4Not yet recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Jul 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of linagliptin and human insulin in type 2 diabetes mellitus (T2DM), sponsored by St Vincent's Hospital Sydney. Primary endpoints: Change in HbA1c and Change in 4-point capillary blood glucose profile. Planned start Jul 2015; status: not yet recruiting.
02
Drugs
linagliptinhuman insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12615000732583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000732583.